MMX™ mesalamine

被引：0
|
作者：
Baker, Danial E. [1 ]
机构：
[1] Washington State Univ, Coll Pharm, Spokane, WA 99210 USA
来源：
REVIEWS IN GASTROENTEROLOGICAL DISORDERS | 2006年 / 6卷 / 03期
关键词：
MMX (TM) mesalamine; ulcerative colitis; Crohn's disease;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System(TM) (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral mesalamine formulation is a once-daily MMX tablet that delivers the mesalamine to the colon, making it most useful in the treatment of ulcerative colitis. The MMX coating matrix and coating system begin dissolution in the final portion of the ileum. This type of oral formulation may make MMX a preferred agent over other oral mesalamine and mesalamine-prodrug formulations that release the drug proximally in the gastrointestinal tract. Unlike previous formulations, it can be administered once daily for the treatment of ulcerative colitis.
引用
收藏
页码：146 / 152
页数：7
相关论文
共 50 条
  • [1] Effects of MMX® Mesalamine Coadministration on the Pharmacokinetics of Metronidazole
    Martin, Patrick
    Pierce, David
    Corcoran, Mary
    Barrett, Karen
    Thompson, Thomas
    Willsie, Sandra
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S679 - S679
  • [2] MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations
    D'Amico, Ferdinando
    Lusetti, Francesca
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. DIGESTIVE AND LIVER DISEASE, 2024, 56 (09) : 1425 - 1432
  • [3] MMX mesalamine: A modern twist on a classic treatment
    Nardone, Olga Maria
    [J]. DIGESTIVE AND LIVER DISEASE, 2024, 56 (09) : 1423 - 1424
  • [4] MMX™ mesalamine (vol 6, pg 148, 2006)
    Baker, Danial E.
    [J]. REVIEWS IN GASTROENTEROLOGICAL DISORDERS, 2006, 6 (04) : 249 - 249
  • [5] Effect of MMX® Mesalamine Coadministration on the Pharmacokinetics of Ciprofloxacin XR
    Martin, Patrick
    Pierce, David
    Corcoran, Mary
    Barrett, Karen
    Thompson, Thomas
    Willsie, Sandra
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S678 - S678
  • [6] Once-Daily MMX Mesalamine in the Management of Ulcerative Colitis
    Blonski, Wojciech
    Buchner, Anna M.
    Lichtenstein, Gary R.
    [J]. CLINICAL MEDICINE INSIGHTS-GASTROENTEROLOGY, 2011, 4 : 7 - 13
  • [7] Budesonide MMX and Mesalamine to Induce Remission in Patients With Ulcerative Colitis
    Criscuoli, Valeria
    Sinagra, Emanuele
    Cottone, Mario
    [J]. GASTROENTEROLOGY, 2013, 144 (03) : E23 - E23
  • [8] Pooled Safety Analysis of Long-term MMX® Mesalamine Administration
    Solomon, Dory
    Paridaens, Kristine
    Palmen, Mary
    Barrett, Karen
    Streck, Paul
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S25 - S25
  • [9] MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis
    Sandborn, W.
    Kamm, M.
    Lichtenstein, G.
    Barrett, K.
    Joseph, R.
    [J]. INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S24 - S24
  • [10] Induction of remission with extended MMX™ mesalamine therapy: time to resolution of UC symptoms
    Sandborn, W.
    Kamm, M.
    Lichtenstein, G.
    Sumner, M.
    Joseph, R.
    [J]. INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S18 - S18
12345